← FDA DRUG APPROVALS

FDA ANDA · ANDA207228

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

Sponsor: AYANA PHARMA LTD

APPLICATION
ANDA207228
TYPE
ANDA
ORIGINAL APPROVAL
2021-10-12
LATEST ACTION
2021-10-12
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE, LIPOSOMAL
MARKETING STATUS
Prescription

Products

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)Prescription
DOXORUBICIN HYDROCHLORIDE 20MG/10ML (2MG/ML) · INJECTABLE, LIPOSOMAL · INJECTION

Approval history

2021-10-12UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →